#MaxHealth is getting ready to heal the pain #SuperChartz

Key Levels:

Support: 830 Closing Basis

Resistance: 900, 999, 1099

Key Drivers:

Max Healthcare Institute Limited, India's second-largest hospital chain, offers a diverse array of healthcare services, including complex procedures like transplants, robotic surgeries, cardiac, neuro, orthopedic, and oncology surgeries. They have 17 facilities with a current capacity of ~3,530 beds, boasting a ~75% occupancy rate. Their Max Lab has 435+ partner-run CCs, 23 CoCCs, and ~170 PAS. Max@Home conducts 3,000+ daily billed transactions and has 14 specialized services. Max MyHealth, their digital platform, accounted for ~21% of H1FY24 revenues. They have significant strategic partnerships with Deakin University and Imperial College London, with ~1,000 high-index journal research publications in the last 5 years and 500 completed clinical research projects. Max recently acquired 550 bedded Sahara Hospital for ~Rs. 940 crs and aims to double its bed capacity with a planned brownfield expansion of ~2600 beds and potential to add 1,000 beds through land parcels. They plan to add beds in NCR as follows: FY24: 300 beds for Rs. 918 crs, FY25: 819 beds for Rs. 1592 crs, FY26: 1100 beds for Rs. 1377 crs, FY27: 521 beds for Rs. 552 crs, FY28: 1350 beds.


The company has a significant market capitalization of ₹84,041 Cr, with its current stock price at ₹865, fluctuating between a high of ₹910 and a low of ₹412. Its price-to-earnings ratio (P/E) stands high at 79.5, indicating investor optimism. The book value per share is ₹80.7, and the dividend yield is 0.12%. It maintains healthy returns with ROCE at 15.0% and ROE at 16.1%. The operating profit margin (OPM) is robust at 27.9%. The company's EPS is ₹10.9, and it demonstrates strong performance compared to the industry with a return over three months at 39.4% and return over three years at 65.2%. The return on assets is 11.4%, showcasing efficient asset utilization. It generated significant sales of ₹5,198 Cr. The enterprise value is ₹82,910 Cr, with an EVEBITDA ratio of 51.0. The debt-to-equity ratio is low at 0.08, reflecting a healthy financial structure. Overall, the company exhibits strong financials, profitability, and market performance.